← 返回

精准医学时代的骨肉瘤管理:文献计量分析与临床进展(2015-2024)

英文原题:Osteosarcoma Management in the Precision Medicine Era: Bibliometric Analysis and Clinical Progress (2015-2024).

查看英文原题

Osteosarcoma Management in the Precision Medicine Era: Bibliometric Analysis and Clinical Progress (2015-2024).

PubMed 2025/01/01(内容时间) Arch Bone Jt Surg Q3 · IF 1.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

将文献计量学见解与临床进展相结合,凸显了骨肉瘤管理中个体化方法的重要性。

中文摘要

骨肉瘤是最常见的高级别恶性骨肿瘤,其治疗选择进展有限,亟需更有效疗法。本综述分析2015—2024年骨肉瘤研究的文献计量趋势和临床进展,重点关注精准医学和个体化治疗。

检索Web of Science核心合集,获得17,476篇骨肉瘤相关出版物进行文献计量分析。使用Bibliometrix R软件包评估发文趋势、国际合作和新兴研究主题等指标。此外,开展临床综述,考察诊断影像、预后生物标志物、化疗耐药、靶向治疗、免疫疗法和手术技术方面的近期创新。

骨肉瘤研究出版物数量稳步增加,2021年达到峰值2,009篇;中国、美国、日本、印度和意大利贡献显著。主要研究主题包括凋亡、转移、化疗耐药和免疫治疗。动态MRI和PET/CT等影像技术进步显著改善肿瘤分期及治疗应答预测。TP53、RB1、MYC等基因改变及炎症标志物等新兴生物标志物已成为重要预后工具。患者特异性器械和保肢手术等创新改善了患者结局。此外,激酶抑制剂、抗体药物偶联物等靶向疗法,以及CAR-T 细胞和免疫检查点抑制剂等免疫疗法,已在临床试验中显示有希望的结果。

将文献计量发现与临床进展整合,凸显了骨肉瘤管理中个体化方法的重要性。预测性影像生物标志物和精准靶向治疗发挥关键作用;未来研究应聚焦临床验证,以改善患者结局。

展开英文摘要原文

Osteosarcoma, the most common high-grade malignant bone tumor, has experienced only limited progress in therapeutic options, highlighting the urgent need for more effective treatments. This review examines bibliometric trends and clinical developments in osteosarcoma research from 2015 to 2024, with a particular focus on precision medicine and personalized therapy.

A search in the Web of Science Core Collection identified 17,476 osteosarcoma-related publications for bibliometric analysis. Key metrics, including publication trends, international collaborations, and emerging research topics, were evaluated using the Bibliometrix R package. Additionally, a clinical review examined recent innovations in diagnostic imaging, prognostic biomarkers, chemotherapy resistance, targeted therapies, immunotherapies, and surgical techniques.

Research publications on osteosarcoma steadily increased, peaking at 2,009 in 2021, with significant contributions from China, the United States, Japan, India, and Italy. Key research themes encompassed apoptosis, metastasis, chemotherapy resistance, and immunotherapy. Advances in imaging techniques, such as dynamic MRI and PET/CT, have significantly enhanced tumor staging and prediction of treatment response. Emerging biomarkers, including genetic alterations (TP53, RB1, MYC) and inflammatory markers, have become important prognostic tools. Surgical innovations, including patient-specific instrumentation and limb-sparing techniques, have improved patient outcomes. Furthermore, targeted therapies (kinase inhibitors, antibody-drug conjugates) and immunotherapies (CAR T-cell therapy, immune checkpoint inhibitors) have demonstrated promising results in clinical trials.

Integrating bibliometric insights with clinical advancements underscores the importance of personalized approaches in osteosarcoma management. Predictive imaging biomarkers and precision-targeted therapies play a crucial role, and future research should focus on their clinical validation to enhance patient outcomes.

论文信息

作者
Jamshidi K、Hajialiloo Sami S、Naghizadeh H、Kargar Shooroki K、Ahmadi R、Khabiri SS
文献类型
综述
期刊
The archives of bone and joint surgery2025
原文标识
PubMed 41509604 · DOI 10.22038/ABJS.2025.87193.3953